All-in-one respiratory aid for asthma patients

AeroDel’s founders, Zahir Jaffer, Shradha Sangwai and K.K.Suraj Rajan, have one common denominator: asthma. This led them to ...

Why air pollution could speed up the onset of dementia and Parkinson’s

Air pollution is causing people in the UK to get chronic illnesses like dementia and Parkinson’s earlier, a new study has ...
The Lancet

Refiloe Masekela: building access to care for childhood lung disease

In the 2000s, when the AIDS pandemic hit South Africa, we were seeing a lot of children dying from HIV. That was just before ...

Asthma and Depression Don’t Mix the Way Scientists Expected

Depressive symptoms are common in people with asthma, but increasing evidence suggests they may be driven by biological processes that differ from those seen in major depressive disorder.

Doctor shares ramipril, lisinopril, perindopril, captopril alert over side-effect

"Examples are ramipril, lisinopril, perindopril, captopril. And all of these are used to treat high blood pressure ." He said ...

UK GP explains 3 causes of persistent cough that aren't Covid

A GP has shared three common causes of a persistent cough and it isn't always Covid, the common cold or the flu ...

Shining light on National Asthma and Allergy Awareness Month

The month of May is known as, National Asthma and Allergy Awareness Month, making it the ultimate time to prioritize ...

Doctors Say These Are the 8 Best Remedies for Getting Rid of Phlegm

Coughing up phlegm feels gross, especially if you’re already dealing with other unpleasant symptoms from a cold or other ...
Naples Daily News

Brush fire smoke poses serious health risks: What to know

Brush fire smoke poses serious health risks, especially for those with lung or heart conditions, children, and the elderly.
MedPage Today

Anti-KIT Drug Shows Strong Efficacy in Chronic Spontaneous Urticaria

New data presented at the American Academy of Allergy, Asthma & Immunology annual meeting highlighted promising results for ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...
The Manila Times

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...